Asma Shaukat, MD, Professor of Medicine at NYU Grossman School of Medicine and outgoing Chair of the Clinical Practice Section for the AGA Council, discussed 13-year Nordic trial findings showing reduced colorectal cancer incidence with colonoscopy screening, along with emerging data on GLP-1 therapies in fatty liver disease and cirrhosis. Bruce Sands, MD, Chief of Gastroenterology and Professor of Medicine at the Icahn School of Medicine at Mount Sinai, presented findings from the DUET-CD study evaluating combination therapy in Crohn’s disease.
Primary and Secondary Prevention of Ischemic Stroke in Elderly Patients with Cardiovascular Disease: The Role of Frailty and Care Pathways. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41745720
Explore how frailty-informed strategies, multidisciplinary care, and sex- and age-related factors impact ischemic stroke prevention in elderly with cardiovascular diseases. Focus ...
Frailty indices aid individualized stroke prevention in elderly with cardiovascular disease, emphasizing multidisciplinary care, antithrombotic strategies, and considering sex- and age-related treatment factors.
Dr. Luke Laughlin (Preventive Cardiologist, Cleveland Clinic) presented the Cardinal trial at ACC 2026, where Tonlamarsen, an investigational antisense oligonucleotide, reduced angiotensinogen by 67% with ongoing dosing and maintained 23% suppression after a single dose. Despite biochemical differences, both groups achieved similar ~7 mmHg systolic BP reductions, suggesting BP lags behind RAAS suppression. The upcoming Cardinal-ASH study will target acute severe hypertension patients to further evaluate its impact.
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41824552
Explore the 2026 guidelines on dyslipidemia management, highlighting new approaches to managing cholesterol and related disorders effectively.
The 2026 guidelines replace the 2018 guidelines, offering updated recommendations for managing dyslipidemia, focusing on evaluation, management, and monitoring of lipid disorders.
A review of the association between abnormal body mass index and oocyte quality - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/42226234/
In recent years, the global prevalence of obesity has witnessed a sharp increase. Abnormal body mass index (BMI) exerts a profound influence on female fertility, particularly on oocyte quality. This...
Review highlights that abnormal BMI—especially obesity—negatively affects oocyte quality through lipotoxicity, mitochondrial dysfunction, oxidative stress, DNA damage, and epigenetic alterations, leading to poorer fertility outcomes and increased miscarriage risk.
